Moderna, Inc. (ETR:0QF)
22.51
-0.72 (-3.10%)
At close: May 13, 2025, 5:30 PM CET
Moderna Revenue
Moderna had revenue of $108.00M USD in the quarter ending March 31, 2025, a decrease of -35.33%. This brings the company's revenue in the last twelve months to $3.18B, down -38.35% year-over-year. In the year 2024, Moderna had annual revenue of $3.24B, down -52.75%.
Revenue (ttm)
$3.18B
Revenue Growth
-38.35%
P/S Ratio
3.04
Revenue / Employee
$547.76K
Employees
5,800
Market Cap
8.94B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 3.24B | -3.61B | -52.75% |
Dec 31, 2023 | 6.85B | -12.42B | -64.45% |
Dec 31, 2022 | 19.26B | 792.00M | 4.29% |
Dec 31, 2021 | 18.47B | 17.67B | 2,200.25% |
Dec 31, 2020 | 803.00M | 743.00M | 1,238.33% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Merck KGaA | 21.16B |
Siemens Healthineers AG | 23.14B |
Fresenius SE & Co. KGaA | 22.13B |
Bayer Aktiengesellschaft | 46.61B |
Fresenius Medical Care AG | 19.49B |
Sartorius Aktiengesellschaft | 3.44B |
Carl Zeiss Meditec AG | 2.08B |
Fielmann Group AG | 2.33B |
Moderna News
- 1 day ago - Why Moderna Merged Its Tech and HR Departments - WSJ
- 5 days ago - Moderna to Present at Upcoming Bernstein's 41st Annual Strategic Decisions Conference (SDC) on May 29, 2025 - Wallstreet:Online
- 5 days ago - Moderna to Present at Upcoming Bernstein's 41st Annual Strategic Decisions Conference (SDC) on May 29, 2025 - Accesswire
- 6 days ago - Moderna's combo Covid and flu mRNA shot outperforms current vaccines in large trial - NBC News
- 11 days ago - SA analyst downgrades: AAPL, SMCI, MRNA, TRIP, IIPR, STLA, TWST - Seeking Alpha
- 12 days ago - Moderna: Regulatory Hurdles And Market Challenges Prompt Downgrade To Sell - Seeking Alpha
- 12 days ago - Moderna Expands Cost-Cutting Program By Up To $1.7 Billion, FDA Approval For Flu/COVID-19 Combo Shot Delayed Into 2026 - Benzinga
- 12 days ago - Moderna Expands Cost-Cutting Program By Up To $1.7 Billion, FDA Approval For Flu/COVID-19 Combo Shot Delayed Into 2026 - Benzinga